147 related articles for article (PubMed ID: 15579375)
1. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Jensen J; Krakauer M; Sellebjerg F
Cytokine; 2005 Jan; 29(1):24-30. PubMed ID: 15579375
[TBL] [Abstract][Full Text] [Related]
2. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
[TBL] [Abstract][Full Text] [Related]
3. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
4. The adhesion molecule and cytokine profile of multiple sclerosis lesions.
Cannella B; Raine CS
Ann Neurol; 1995 Apr; 37(4):424-35. PubMed ID: 7536402
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis.
Kraus J; Bauer R; Chatzimanolis N; Engelhardt B; Tofighi J; Bregenzer T; Kuehne BS; Stolz E; Blaes F; Morgen K; Traupe H; Kaps M; Oschmann P
J Neurol; 2004 Apr; 251(4):464-72. PubMed ID: 15083294
[TBL] [Abstract][Full Text] [Related]
6. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer.
Lou J; Gasche Y; Zheng L; Giroud C; Morel P; Clements J; Ythier A; Grau GE
Lab Invest; 1999 Aug; 79(8):1015-25. PubMed ID: 10462039
[TBL] [Abstract][Full Text] [Related]
7. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis.
Graber J; Zhan M; Ford D; Kursch F; Francis G; Bever C; Panitch H; Calabresi PA; Dhib-Jalbut S
J Neuroimmunol; 2005 Apr; 161(1-2):169-76. PubMed ID: 15748956
[TBL] [Abstract][Full Text] [Related]
9. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
[TBL] [Abstract][Full Text] [Related]
10. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
11. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF
Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530
[TBL] [Abstract][Full Text] [Related]
12. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
[TBL] [Abstract][Full Text] [Related]
13. Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution.
Laplaud DA; Ruiz C; Wiertlewski S; Brouard S; Berthelot L; Guillet M; Melchior B; Degauque N; Edan G; Brachet P; Damier P; Soulillou JP
Brain; 2004 May; 127(Pt 5):981-95. PubMed ID: 14985265
[TBL] [Abstract][Full Text] [Related]
14. Expression of costimulatory molecules and cytokines in CSF and peripheral blood mononuclear cells from multiple sclerosis patients.
Monteyne P; Van Antwerpen MP; Sindic CJ
Acta Neurol Belg; 1999 Mar; 99(1):11-20. PubMed ID: 10218088
[TBL] [Abstract][Full Text] [Related]
15. IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells.
Detournay O; Mazouz N; Goldman M; Toungouz M
Hum Immunol; 2005 May; 66(5):460-8. PubMed ID: 15935883
[TBL] [Abstract][Full Text] [Related]
16. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E
Brain; 2006 Jan; 129(Pt 1):200-11. PubMed ID: 16280350
[TBL] [Abstract][Full Text] [Related]
17. Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis.
Saxena N; Aggarwal A; Misra R
J Rheumatol; 2005 Jul; 32(7):1349-53. PubMed ID: 15996076
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis: interferon-beta induces CD123(+)BDCA2- dendritic cells that produce IL-6 and IL-10 and have no enhanced type I interferon production.
Huang YM; Adikari S; Båve U; Sanna A; Alm G
J Neuroimmunol; 2005 Jan; 158(1-2):204-12. PubMed ID: 15589055
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.
Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ
J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245
[TBL] [Abstract][Full Text] [Related]
20. [Changes in lymphocyte subsets s and treatment with beta interferon in active multiple sclerosis].
Gata JM; García-Moreno JM; Dinca L; Sánchez-Margalet V; Navarro G; Izquierdo G
Rev Neurol; 1998 Dec; 27(160):939-42. PubMed ID: 9951008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
